Photo taken from Georges Gebrael/X
Apr 4, 2024, 20:02
Georges Gebrael: RWD of Cabozantinib and ICI vs. cabozantinib monotherapy align with CONTACT03 trial results
Georges Gebrael, Research Fellow at Huntsman Cancer Institute and University of Utah, shared on X/Twitter:
“Just in ACS Journal Cancer. Patients with clear cell mRCC kidney cancer from real world Flatiron database status post ICI treatment, similar survival with cabozantinib and ICI vs. cabozantinib monoRx aligning with CONTACT03 trial results.”
Source: Georges Gebrael/X
